Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Capital Expenditures (2024 - 2025)

Bioregenx (BRGX) has 2 years of Capital Expenditures data on record, last reported at $6000.0 in Q3 2025.

  • For Q3 2025, Capital Expenditures changed N/A year-over-year to $6000.0; the TTM value through Sep 2025 reached $6000.0, down 96.83%, while the annual FY2024 figure was $189390.0, N/A changed from the prior year.
  • Capital Expenditures reached $6000.0 in Q3 2025 per BRGX's latest filing, down from $189390.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $189390.0 in Q1 2024 and bottomed at $6000.0 in Q3 2025.